NO20076468L - Injectable compositions and methods for preparing such compositions - Google Patents
Injectable compositions and methods for preparing such compositionsInfo
- Publication number
- NO20076468L NO20076468L NO20076468A NO20076468A NO20076468L NO 20076468 L NO20076468 L NO 20076468L NO 20076468 A NO20076468 A NO 20076468A NO 20076468 A NO20076468 A NO 20076468A NO 20076468 L NO20076468 L NO 20076468L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- methods
- preparing
- cox
- inhibitor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000007918 intramuscular administration Methods 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 208000025978 Athletic injury Diseases 0.000 abstract 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000008765 Sciatica Diseases 0.000 abstract 1
- 201000002661 Spondylitis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det beskrives ny og meget stabile farmasøytiske sammensetninger omfattende i det minste en syklooksygenase II enzym (COX-II) inhibitor eller ikke-steroidale antiinflammatoriske medikament (NSAID) eller COX/LOX inhibitor, eller dets tautomere former, analoger, isomerer, polymorger, solvater, prodrug eller salter derav som aktive ingredienser egnet for parenteral administrering, fortrinnsvis via intramuskulær (IM) eller intravenøs (IV) rute; fremgangsmåter for å fremstille slike sammensetninger og terapeutiske metoder for anvendelse av slike sammensetninger tilveiebringes. De analgetiske og antiinflammatoriske injiserbare sammensetninger i følge oppfinnelsen er svært nyttige i pattedyr, spesielt i mennesker, for behandling av akutte smertefulle tilstander så som en eller flere av postoperativt traume, smerte assosiert med cancer, idrettskader, migrene hodepine, nevrologisk smerte og smerte assosiert med isjias og spondylitt og lignende, og/eller kroniske smertefulle tilstander, og/eller tilhørende forstyrrelser så som inflammasjon, feber, allergi eller lignende.New and highly stable pharmaceutical compositions comprising at least one cyclooxygenase II enzyme (COX-II) inhibitor or non-steroidal anti-inflammatory drug (NSAID) or COX / LOX inhibitor, or its tautomeric forms, analogs, isomers, polymers, solvates, prodrugs or salts thereof as active ingredients suitable for parenteral administration, preferably via intramuscular (IM) or intravenous (IV) route; methods for preparing such compositions and therapeutic methods for using such compositions are provided. The analgesic and anti-inflammatory injectable compositions of the invention are very useful in mammals, especially in humans, for the treatment of acute painful conditions such as one or more of post-operative trauma, pain associated with cancer, sports injuries, migraine headaches, neurological pain and pain associated with sciatica and spondylitis and the like, and / or chronic painful conditions, and / or associated disorders such as inflammation, fever, allergy or the like.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1357DE2005 | 2005-05-27 | ||
| PCT/IN2006/000177 WO2006126214A2 (en) | 2005-05-27 | 2006-05-25 | Injectable compositions and process for preparation of such compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076468L true NO20076468L (en) | 2008-02-27 |
Family
ID=36917368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076468A NO20076468L (en) | 2005-05-27 | 2007-12-14 | Injectable compositions and methods for preparing such compositions |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1895983A2 (en) |
| JP (1) | JP2008542260A (en) |
| KR (1) | KR20080016689A (en) |
| CN (1) | CN101217939A (en) |
| AU (1) | AU2006250765A1 (en) |
| BR (1) | BRPI0611170A2 (en) |
| CA (1) | CA2609242A1 (en) |
| CR (1) | CR9616A (en) |
| EA (1) | EA200702646A1 (en) |
| MX (1) | MX2007014862A (en) |
| NO (1) | NO20076468L (en) |
| RS (1) | RS20070461A (en) |
| TN (1) | TNSN07482A1 (en) |
| WO (1) | WO2006126214A2 (en) |
| ZA (1) | ZA200711068B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103181893A (en) | 2007-09-07 | 2013-07-03 | 联合治疗公司 | Buffer solutionsha ving selective bactericidal activity against gramnegative bacteria and methods of using same |
| KR20140014350A (en) * | 2009-03-12 | 2014-02-06 | 큠버랜드 파마슈티컬즈 인코포레이티드 | Administration of intravenous ibuprofen |
| US8871810B2 (en) | 2009-07-15 | 2014-10-28 | Cumberland Pharmaceuticals Inc. | Treating critically ill patients with intravenous ibuprofen |
| CN102335114B (en) * | 2010-07-23 | 2015-07-15 | 重庆医药工业研究院有限责任公司 | Stable ibuprofen arginine injection and preparation method thereof |
| CN102370615B (en) * | 2010-08-19 | 2013-09-04 | 四川科伦药物研究有限公司 | Ibuprofen injection preparation and preparation method thereof |
| WO2013058303A1 (en) | 2011-10-18 | 2013-04-25 | ラクオリア創薬株式会社 | Medicinal composition |
| CN102512383A (en) * | 2011-12-25 | 2012-06-27 | 天津市嵩锐医药科技有限公司 | Parecoxib sodium pharmaceutical composition for injection |
| US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| CN103372216B (en) * | 2012-04-26 | 2015-05-06 | 北京京卫燕康药物研究所有限公司 | Solid medical composition containing celecoxib |
| TWI646091B (en) | 2012-12-28 | 2019-01-01 | 日商衛斯克慧特股份有限公司 | Salt and crystal form |
| US20140187635A1 (en) | 2012-12-28 | 2014-07-03 | Themis Medicare Limited | Diclofenac compositions |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| CN103263385B (en) * | 2013-05-17 | 2016-04-27 | 江苏正大清江制药有限公司 | A kind of celecoxib long-acing nano injection and preparation method thereof |
| US20180000940A1 (en) * | 2014-12-20 | 2018-01-04 | Troikaa Pharmaceuticals Limited | Injectable formulations of paracetamol |
| WO2016170401A1 (en) * | 2015-04-20 | 2016-10-27 | Umedica Laboratories Pvt. Ltd | Novel injectable composition of diclofenac sodium |
| CN107303266B (en) * | 2016-04-18 | 2020-09-08 | 重庆润泽医药有限公司 | Levo-oxiracetam injection and preparation method thereof |
| CN107303264A (en) * | 2016-04-18 | 2017-10-31 | 重庆润泽医药有限公司 | Non-foam levo-oxiracetam parenteral solution and preparation method thereof |
| FR3077984B1 (en) * | 2018-02-16 | 2020-02-21 | Vetoquinol Sa | MULTI-PURPOSE COMPOSITION OF TORASEMIDE |
| CN109498852B (en) * | 2018-12-29 | 2022-06-24 | 广州噢斯荣医药技术有限公司 | Biodegradable material for treating orthopedic diseases and application thereof |
| CN111103381A (en) * | 2019-12-25 | 2020-05-05 | 南京希麦迪医药科技有限公司 | Method for determining nimesulide concentration in human plasma by liquid chromatography-mass spectrometry |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389681A (en) * | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| IT1283252B1 (en) * | 1996-03-15 | 1998-04-16 | Pulitzer Italiana | SOLUTIONS OF PIROXICAM INJECTABLE BY PARENTERAL WAY |
| IN187306B (en) * | 1998-01-12 | 2002-03-23 | Panacea Biotec Ltd | |
| PE20021017A1 (en) * | 2001-04-03 | 2002-11-24 | Pharmacia Corp | RECONSTITUABLE PARENTERAL COMPOSITION |
| AU2003249510A1 (en) * | 2002-08-12 | 2004-02-25 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
-
2006
- 2006-05-25 BR BRPI0611170-0A patent/BRPI0611170A2/en not_active IP Right Cessation
- 2006-05-25 AU AU2006250765A patent/AU2006250765A1/en not_active Abandoned
- 2006-05-25 KR KR1020077030585A patent/KR20080016689A/en not_active Ceased
- 2006-05-25 ZA ZA200711068A patent/ZA200711068B/en unknown
- 2006-05-25 WO PCT/IN2006/000177 patent/WO2006126214A2/en not_active Ceased
- 2006-05-25 RS RSP-2007/0461A patent/RS20070461A/en unknown
- 2006-05-25 CN CNA2006800250937A patent/CN101217939A/en active Pending
- 2006-05-25 JP JP2008513009A patent/JP2008542260A/en not_active Withdrawn
- 2006-05-25 CA CA002609242A patent/CA2609242A1/en not_active Abandoned
- 2006-05-25 EP EP06756263A patent/EP1895983A2/en not_active Withdrawn
- 2006-05-25 MX MX2007014862A patent/MX2007014862A/en not_active Application Discontinuation
- 2006-05-25 EA EA200702646A patent/EA200702646A1/en unknown
-
2007
- 2007-12-14 NO NO20076468A patent/NO20076468L/en not_active Application Discontinuation
- 2007-12-19 CR CR9616A patent/CR9616A/en not_active Application Discontinuation
- 2007-12-21 TN TNP2007000482A patent/TNSN07482A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0611170A2 (en) | 2010-08-17 |
| ZA200711068B (en) | 2009-03-25 |
| CA2609242A1 (en) | 2006-11-30 |
| JP2008542260A (en) | 2008-11-27 |
| CN101217939A (en) | 2008-07-09 |
| CR9616A (en) | 2008-10-30 |
| WO2006126214A2 (en) | 2006-11-30 |
| WO2006126214A3 (en) | 2007-06-07 |
| TNSN07482A1 (en) | 2009-03-17 |
| AU2006250765A1 (en) | 2006-11-30 |
| KR20080016689A (en) | 2008-02-21 |
| EA200702646A1 (en) | 2008-06-30 |
| MX2007014862A (en) | 2008-02-21 |
| EP1895983A2 (en) | 2008-03-12 |
| RS20070461A (en) | 2008-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20076468L (en) | Injectable compositions and methods for preparing such compositions | |
| CY1122336T1 (en) | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | |
| DK1742624T3 (en) | Dopamine agonist combination therapy with sedatives to improve sleep quality | |
| CL2011000101A1 (en) | Compounds derived from substituted pyridazine; hedgehog and smo signaling inhibitors; pharmaceutical composition; and use for the treatment of disorders or syndromes associated with hyperproliferative diseases. | |
| MX2009002893A (en) | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates. | |
| DK1970059T3 (en) | Calcium dobesilate drug for the treatment and prophylaxis of tendon disorders | |
| NO20060424L (en) | 5-heteroration-based P38 kinase inhibitors | |
| DK1505973T3 (en) | Multiple myeloma treatment combinations | |
| ECSP077421A (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1 | |
| MX2010002278A (en) | Antiviral drugs for treatment of arenavirus infection. | |
| AR109590A2 (en) | POSTOLOGICAL REGIME FOR COMT INHIBITORS | |
| NO20051726L (en) | Pyrimidinone derivatives as therapeutic agents for acute and chronic inflammatory, ischemic and remodeling processes | |
| ATE456565T1 (en) | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | |
| CL2008002294A1 (en) | Compounds derived from benzothiazole acetamide and their pharmaceutically acceptable salts; pharmaceutical composition of said compounds; its use to treat py3 kinase mediated diseases including melanoma, carcinoma and other conditions derived from cancer. | |
| MX377802B (en) | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS. | |
| BR112013026202A2 (en) | compositions and therapeutic uses of epsilon kinase inhibitors related to ikk and tank binding kinase i | |
| SV2009003283A (en) | AKT ACTIVITY INHIBITORS | |
| CY1116215T1 (en) | Combination therapy for the therapeutic treatment of Protein Deficiency Disorders | |
| EA200802166A1 (en) | STABLE PHARMACEUTICAL COMPOSITION WITH PROTECTIVE ACTION AGAINST IRRITATION (OPTIONS), METHOD FOR ITS PREPARATION AND METHOD OF TREATING CALCIUM MIMETIC WITH IT WITH HELP | |
| AR060836A1 (en) | A TRANS-MUCOSA DISK TO ADMINISTER AN ACTIVE AGENT, A TRANS-MUCOSA COMPOSITION AND THE METHOD OF ADMINISTRATION OBTAINED | |
| JOP20240235A1 (en) | Aryl heterocyclic compounds for pain relief | |
| ATE489371T1 (en) | BENZAMIDE GLUCOCINASE ACTIVATORS | |
| ATE542800T1 (en) | KINASE INHIBITORS AND THEIR METHODS OF APPLICATION | |
| ATE527243T1 (en) | CALCIUM CHANNEL ANTAGONISTS OF THE QUINAZOLINONE T TYPE | |
| EA200901237A1 (en) | APPLICATION OF DIMIRACETAM IN THE TREATMENT OF CHRONIC PAIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |